The TGFBI gene and protein expression in topotecan resistant ovarian cancer cell lines

Li, 2022, Drug resistance in cancers: a free pass for bullying, Cells, 11, 3383, 10.3390/cells11213383 Vasan, 2019, A view on drug resistance in cancer, Nature, 575, 299, 10.1038/s41586-019-1730-1 Chatterjee, 2019, Polytherapy and targeted cancer drug resistance, Trends Cancer, 5, 170, 10.1016/j.trecan.2019.02.003 Bukowski, 2020, Mechanisms of multidrug resistance in cancer chemotherapy, Int J Mol Sci, 21, 3233, 10.3390/ijms21093233 Nussinov, 2021, Anticancer drug resistance: an update and perspective, Drug Resist Updates, 59, 10.1016/j.drup.2021.100796 Huang, 2021, CAM-DR: mechanisms, roles and clinical application in tumors, Front Cell Dev Biol, 9 2009, Ovarian Cancer, 80 Kossaï, 2018, Ovarian cancer: a heterogeneous disease, Pathobiology, 85, 41, 10.1159/000479006 Zhang, 2023, New trends in diagnosing and treating ovarian cancer using nanotechnology, Front Bioeng Biotechnol, 11 Steitz, 2020, Tumor-associated macrophages promote ovarian cancer cell migration by secreting transforming growth factor beta induced (TGFBI) and tenascin C, Cell Death Dis, 11, 249, 10.1038/s41419-020-2438-8 Lee, 2019, New strategies in ovarian cancer treatment, Cancer, 125, 4623, 10.1002/cncr.32544 Maiorano, 2023, Olaparib and advanced ovarian cancer: summary of the past and looking into the future, Front Pharmacol, 14, 10.3389/fphar.2023.1162665 Wojtowicz, 2021, Piperine targets different drug resistance mechanisms in human ovarian cancer cell lines leading to increased sensitivity to cytotoxic drugs, Int J Mol Sci, 22, 4243, 10.3390/ijms22084243 Ding P, Gao Y, Wang J, Xiang H, Zhang C, Wang L, et al. Progress and challenges of multidrug resistance proteins in diseases n.d. Januchowski, 2017, Microarray-based detection and expression analysis of new genes associated with drug resistance in ovarian cancer cell lines, Oncotarget, 8, 49944, 10.18632/oncotarget.18278 Raglow, 2015, Tumor matrix protein collagen XIα1 in cancer, Cancer Lett, 357, 448, 10.1016/j.canlet.2014.12.011 Januchowski, 2016, Increased expression of several collagen genes is associated with drug resistance in ovarian cancer cell lines, J Cancer, 7, 1295 Sterzyńska, 2018, The role of matrix gla protein (MGP) expression in paclitaxel and topotecan resistant ovarian cancer cell lines, Int J Mol Sci, 19, 2901, 10.3390/ijms19102901 Januchowski, 2014, Extracellular matrix proteins expression profiling in chemoresistant variants of the A2780 ovarian cancer cell line, BioMed Res Int, 2014, 1, 10.1155/2014/365867 Sterzyńska, 2019, Expression of osteoblast-specific factor 2 (OSF-2, periostin) is associated with drug resistance in ovarian cancer cell lines, Int J Mol Sci, 20, 3927, 10.3390/ijms20163927 Klejewski, 2017, The significance of lumican expression in ovarian cancer drug-resistant cell lines, Oncotarget, 8, 74466, 10.18632/oncotarget.20169 Sterzyńska, 2018, Myotilin, a new topotecan resistant protein in ovarian cancer cell lines, J Cancer, 9, 4413 Ween, 2012, Transforming growth factor-beta-induced protein (TGFBI)/(βig-H3): a matrix protein with dual functions in ovarian cancer, Int J Mol Sci, 13, 10461, 10.3390/ijms130810461 LeBaron, 1995, βIG-H3, a novel secretory protein inducible by transforming growth factor-β, is present in normal skin and promotes the adhesion and spreading of dermal fibroblasts in vitro, J Invest Dermatol, 104, 844, 10.1111/1523-1747.ep12607024 Hashimoto K, Noshiro M, Ohno S, Kawamoto T, Satakeda H, Akagawa Y, et al. Characterization of a cartilage-derived 66-kDa protein ž RGD-CAPrb ig-h3/that binds to collagen n.d. Gibson, 1997, Immunohistochemical and ultrastructural localization of MP78/70 (βig-h3) in extracellular matrix of developing and mature bovine tissues, J Histochem Cytochem, 45, 1683, 10.1177/002215549704501212 Kim, 2000, Identification of motifs for cell adhesion within the repeated domains of transforming growth factor-β-induced gene,βig-h3, J Biol Chem, 275 Costanza, 2019, Transforming growth factor beta-induced, an extracellular matrix interacting protein, enhances glycolysis and promotes pancreatic cancer cell migration, Int J Cancer, 145, 1570, 10.1002/ijc.32247 Yuan, 2022, The value of the stemness index in ovarian cancer prognosis, Genes, 13, 993, 10.3390/genes13060993 Han, 2015, The role of TGFBI (βig-H3) in gastrointestinal tract tumorigenesis, Mol Cancer, 14, 64, 10.1186/s12943-015-0335-z Zhu, 2011, Neutralizing monoclonal antibody to periostin inhibits ovarian tumor growth and metastasis, Mol Cancer Therapeut, 10, 1500, 10.1158/1535-7163.MCT-11-0046 Tumbarello, 2012, β3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells, Mol Cancer, 11, 36, 10.1186/1476-4598-11-36 Tumbarello, 2016, SPARC regulates transforming growth factor beta induced (TGFBI) extracellular matrix deposition and paclitaxel response in ovarian cancer cells, PLoS One, 11, 10.1371/journal.pone.0162698 Hernandez, 2016, Characterization of ovarian cancer cell lines as in vivo models for preclinical studies, Gynecol Oncol, 142, 332, 10.1016/j.ygyno.2016.05.028 Stukova, 2015, Reduced accumulation of platinum drugs is not observed in drug-resistant ovarian cancer cell lines derived from cisplatin-treated patients, J Inorg Biochem, 149, 45, 10.1016/j.jinorgbio.2015.05.003 Januchowski, 2013, MDR gene expression analysis of six drug-resistant ovarian cancer cell lines, BioMed Res Int, 2013, 1, 10.1155/2013/241763 Sterzyńska, 2018, Mutual expression of ALDH1A1, LOX, and collagens in ovarian cancer cell lines as combined CSCs- and ECM-related models of drug resistance development, Int J Mol Sci, 20, 54, 10.3390/ijms20010054 Zhou, 2022, Systematic identification of key extracellular proteins as the potential biomarkers in lupus nephritis, Front Immunol, 13 Wojtowicz, 2016, Effect of brefeldin A and castanospermine on resistant cell lines as supplements in anticancer therapy, Oncol Rep, 35, 2896, 10.3892/or.2016.4656 Wang, 2012, TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer, J Exp Clin Cancer Res, 31, 6, 10.1186/1756-9966-31-6 Nowacka, 2021, The significance of HERC5, IFIH1, SAMD4, SEMA3A and MCTP1 genes expression in resistance to cytotoxic drugs in ovarian cancer cell lines, Med J Cell Biol, 9, 138, 10.2478/acb-2021-0019 Zwimpfer, 2023, Low grade serous ovarian cancer – a rare disease with increasing therapeutic options, Cancer Treat Rev, 112, 10.1016/j.ctrv.2022.102497 Issa, 2009, Estrogen receptor gene amplification occurs rarely in ovarian cancer, Mod Pathol, 22, 191, 10.1038/modpathol.2008.130 Bogush, 2018, Estrogen receptors alpha and beta in ovarian cancer: expression level and prognosis, Dokl Biochem Biophys, 482, 249, 10.1134/S1607672918050058 Corona, 2021, The role of the extracellular matrix protein TGFBI in cancer, Cell Signal, 84, 10.1016/j.cellsig.2021.110028 Wei, 2021, Identification of hypoxia signature to assess the tumor immune microenvironment and predict prognosis in patients with ovarian cancer, Internet J Endocrinol, 2021, 1, 10.1155/2021/4156187 Karlan, 2014, POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer, Gynecol Oncol, 132, 334, 10.1016/j.ygyno.2013.12.021 Xu, 2021, Mining TCGA database for gene expression in ovarian serous cystadenocarcinoma microenvironment, PeerJ, 9, 10.7717/peerj.11375 Pan, 2020, A novel six-gene signature for prognosis prediction in ovarian cancer, Front Genet, 11, 1006, 10.3389/fgene.2020.01006 2017, New and old genes associated with topotecan resistance development in ovarian cancer cell lines, Anticancer Res, 37, 1625, 10.21873/anticanres.11493 Świerczewska, 2019, PTPRK expression is downregulated in drug resistant ovarian cancer cell lines, and especially in ALDH1A1 positive CSCs-like populations, Int J Mol Sci, 20, 2053, 10.3390/ijms20082053 Świerczewska, 2018, New and old genes associated with primary and established responses to paclitaxel treatment in ovarian cancer cell lines, Molecules, 23, 891, 10.3390/molecules23040891 Xiao, 2015, Periostin induces chemoresistance in colon cancer cells through activation of the PI3K/Akt/survivin pathway: periostin in Colon Cancer, Biotechnol Appl Biochem, 62, 401, 10.1002/bab.1193 Ricciardelli, 2016, Women in cancer thematic review: ovarian cancer–peritoneal cell interactions promote extracellular matrix processing, Endocr Relat Cancer, 23, T155, 10.1530/ERC-16-0320 Li, 2012, The role of TGFBI in mesothelioma and breast cancer: association with tumor suppression, BMC Cancer, 12, 239, 10.1186/1471-2407-12-239 Ahmed, 2007, The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel, Cancer Cell, 12, 514, 10.1016/j.ccr.2007.11.014 Liu, 2022, Bioinformatics analysis of key biomarkers for bladder cancer, Biomed Rep, 18, 14, 10.3892/br.2022.1596 Poplawski, 2023, Coordinated reprogramming of renal cancer transcriptome, metabolome and secretome associates with immune tumor infiltration, Cancer Cell Int, 23, 2, 10.1186/s12935-022-02845-y Zhang, 2022, Hub gene target of glioblastoma: LOX, SERPINH1 and TGFBI, Medicine (Baltim), 101 Zou, 2019, Secreted TGF-beta-induced protein promotes aggressive progression in bladder cancer cells, Cancer Manag Res, 11, 6995, 10.2147/CMAR.S208984 Goehrig, 2019, Stromal protein βig-h3 reprogrammes tumour microenvironment in pancreatic cancer, Gut, 68, 693, 10.1136/gutjnl-2018-317570 Zhu J, Chen X, Liao Z, He C, Hu X. TGFBI protein high expression predicts poor prognosis in colorectal cancer patients n.d.